VIM and non-small cell lung carcinoma: When NSCLC became resistance to gefitinib, EMT could not be blocked by gefitinib whereas addition of a PAR2 inhibitor notably sensitized gefitinib to up-regulate E-cadherin and down-regulate vimentin, consequently overcoming EMT-related drug resistance (Figures 3F–K).